2018
DOI: 10.1016/j.ihj.2018.08.008
|View full text |Cite
|
Sign up to set email alerts
|

Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications

Abstract: Increased heart rate (HR) is associated with deleterious effects on several disease conditions. Chronic heart failure (CHF) is one of the cardiovascular diseases with recurrent hospitalization burden and an ongoing drain on health-care expenditure. Despite advancement in medicine, management of CHF remains a challenge to health-care providers. Ivabradine selectively and specifically inhibits the pacemaker I(f) ionic current which reduces the cardiac pacemaker activity. The main effect of ivabradine therapy is … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(14 citation statements)
references
References 63 publications
0
7
0
Order By: Relevance
“…Ivabradine is the sole available HCN (hyperpolarization-activated cyclic nucleotidegated) inhibitor. It slows HR by reduction of the If current-regulated diastolic depolarization in the sinoatrial node, increasing diastolic time without altering the action potential duration or causing negative inotropy [7].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Ivabradine is the sole available HCN (hyperpolarization-activated cyclic nucleotidegated) inhibitor. It slows HR by reduction of the If current-regulated diastolic depolarization in the sinoatrial node, increasing diastolic time without altering the action potential duration or causing negative inotropy [7].…”
Section: Discussionmentioning
confidence: 99%
“…Caution is required in patients with creatinine clearance below 15 ml/min. Ivabradine is contraindicated in patients with severe liver damage [7].…”
Section: Less Common Adverse Effectsmentioning
confidence: 99%
See 1 more Smart Citation
“…In addition, it prolongs diastolic perfusion time and improves coronary flow velocity reserves. These physiological changes result into an increased ischemic threshold and an improvement in angina [33]. Ivabradine reduces HR almost linearly with an oral dose ranging from 0.5 to 24 mg.…”
Section: Ivabradine For the Treatment Of Potsmentioning
confidence: 99%
“…Adequate control of heart rate decreases the incidence of MACE and the frequency of hospitalization [7]. Ivabradine is added for patients who had inadequate control of heart rate with a maximum dose of beta-blocker, or who have reached a maximum tolerable dose, or who are intolerant to beta-blocker, to decrease the incidence of both hospitalization and adverse cardiac outcomes [8]. Due to minimal studies on ivabradine in chronic heart failure patients in the Indian population, we have done this prospective, observational study to assess the clinical effectiveness of ivabradine plus beta-blocker versus betablocker alone in addition to standard care in reducing hospitalization and major adverse cardiovascular event in patients with chronic heart failure.…”
Section: Introductionmentioning
confidence: 99%